Ensuring the Safety and Authenticity of Pharmaceutical Drugs with Innovative Packaging Technologies

The World Health Organization (WHO) currently estimates the global trade in counterfeit drugs to be worth £75 billion, with continued growth predicted to be at a staggering rate of 13% a year. As the counterfeit trade grows, criminals are becoming increasingly sophisticated and capable in the way they package their products. Richard Burhouse of Payne Security explains the global regulatory bodies that have introduced strict legislation to ensure maximum security of pharmaceutical packaging.

Read more

Good Pallet Practice – Product Recalls Highlight Need for Clearer Guidance

Many countries have legislation that requires pharmaceutical and medical device companies to follow good manufacturing practice (GMP) and good distribution practice (GDP) guidelines to ensure the proper production and distribution of medicinal products for human use. In Europe, the EU GDP guidelines (94/C 63/03) offer companies guidance on personnel, documentation, premises and equipment, deliveries to customers, returns and self-inspections. Jim Hardisty of Goplasticpallets.com considers why guidelines fail to address one key element in the distribution process: the use of pallets.

Read more

The End of the Defective Carton?

Pharmaceutical packaging manufacturers have become the trailblazers of the packaging world when it comes to ensuring carton quality. In every pharma packaging plant, multiple checks are carried out right through the production process from sales, through design and print, to die-cutting, gluing, and beyond. Yet even this is not enough to ensure the ‘zero fault’ supply that brand owners increasingly require. Jacques Reymond from Bobst explains what carton makers can do from now on.

Read more

Recent Advances in Raman and Surface-Enhanced Raman Spectroscopy: Pharmaceutical, Forensic and Biomedical Applications

Iqbal T Shadi from Imperial College London NHLI and Roy Goodacre, Professor of Biological Chemistry at University of Manchester, explore how Raman spectroscopy has advanced in recent years, and how its use in both industry and academia has increased significantly and is redrawing the landscape in many fields, such as biomedical and pharmaceutical R&D.

Read more

Selecting a CDMO: How to Stop Partnering Ending in a Messy Divorce

Big changes have occurred recently in the pharmaceutical industry – not unlike other industries and the wider economy in response to globalisation – notably, that smaller biotech and life science com-panies are struggling to access capital, whilst many big pharma companies have downsized and out-sourced research in order to drive down costs. Torkel Gren of Recipharm Pharmaceutical Develop-ment AB discusses the best approach to take, while selecting the right contract development and manufacturing companies.

Read more

Sustainable High Technology Cooling Systems are Meeting the Need for Energy-Efficient Ultra Low Refrigeration

William B White, CEO, Offenberger & White, Inc highlights the reason why the process of purchasing ultra low temperature freezers and acknowledging impact on facility overhead budgets is forcing a transition in buying authority from a single user working on grant money to comprehensive evaluations by financial, environmental and sustainability departments throughout the institution.

Read more

Integrated Innovation – Genomic Biomarker Discovery, Development and Application

The significance of biomarkers as diagnostic and predictive tools with clinical utility and for monitoring and judgment of study progress probably cannot be overestimated. Co-development and extended use of biomarkers throughout the entire drug development process, referred to as `companion diagnostics´, are considered to yield significant increases in study effectiveness. Ioannis Amarantos, Thomas Laufer and Thomas Brefort of Febit Biomed GmbH explain how integrative, combinatorial approaches assessing multiple genomic biomarkers will potentiate the power and complement cellular, protein and metabolic biomarker data.

Read more

Comparative Effectiveness Research – What’s Old is New Again

“Comparative effectiveness” has become a popular phrase in political and health policy circles worldwide since the US Congress passed the Patient Protection and Affordable Care Act of 2010.
The current interest in comparative effectiveness research is driven by the desire to identify treatment options that are more effective than others and offer good “value for money”. While head-to-head research can yield valuable insights on effectiveness and cost-effectiveness, care must be taken to ensure comparability across the populations studied. Mason W Russell of PharmaNet discusses that once this data is collected, it can be used in conjunction with costs and other economic data within a modelling framework to estimate cost-effectiveness and budget impact of treatment options.

Read more

Effective Partnering with Niche Oncology CROs to Meet Evolving Clinical Development Needs

Clinical development plans require efficiency, expertise and agility in a rapidly changing regulatory and treatment environment. Meghann Smith and Kathy Burruss of Ockham explain the major points of consideration regarding the ability to strategically guide compounds through the clinical development process in a cost-effective manner by utilisation of a niche oncology CRO.

Read more

The New CRO Role: Will it Reverse Declining Patient Enrolment?

The cost of patient enrolment is now the single largest part of the total trial budget, representing 32% of the cost. Among CROs and sponsors, this expense has been accepted as the inevitable cost of trial management, but it no longer should be. Richard Malcolm of Acurian considers what impact the emerging CRO/sponsor strategic partnerships that represent the latest trend in the CRO industry will have on patient enrolment.

Read more